Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

Principal Investigator

Mary Brunette

Study Number

F09040

Summary

The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol. The second aim will serve to further assess the effects of dronabinol on symptoms and medication side effects in this population.

Phase

II

Available at the following location(s)

• Manchester

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms